Depomed Inc (NASDAQ:DEPO) stock was up 11.45 percent during trading on 3rd March on the back of strong preliminary results reported by the pharmaceutical firm on 25th February. It also reported on the same day that it would acquire the complete rights of the fast selling drug CAMBIA from drug firm Nautilus Neurosciences. The drug which is also known by its chemical name of diclofenac potassium is an oral solution. Depomed Inc (NASDAQ:DEPO) stock opened at $13.62 in last session, and closed at $14.02, while the day range of DEPO stock is $13.44-$14.19.The stock showed a positive weekly performance of 9.96%.
Synta Pharmaceuticals Corp.(NASDAQ:SNTA) On Mar. 3 announced that Safi R. Bahcall, Ph.D., has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective immediately, and has been replaced by a newly formed Executive Committee of the Board. The Committee will be chaired by Keith R. Gollust, the Company’s Chairman of the Board of Directors, and include current Director Robert N. Wilson, retired Vice Chairman of Johnson & Johnson, and newly appointed Director Paul A. Friedman, M.D., the former Chief Executive Officer of Incyte Corporation. The committee will serve as the principal executive body for the Company until such time as a Chief Executive Officer is named. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock opened at $5.97, in last session and closed at $6.45, by gained 4.88%.The 52 week range was $3.70-$10.74.Company’s market capitalization is $445.74 million.
McDermott International (NYSE: MDR) reported fourth quarter and full-year 2013 results after markets closed Monday. The offshore oilfield engineering and construction firm posted a diluted earnings per share (EPS) loss of $1.37 per share on revenues of $517.34 million. For the fourth quarter of 2012 the company posted EPS of $0.17 on revenues of $995.95 million. McDermott International (NYSE:MDR) stock loosed -8.26% and finished the last session at $7.44.The EPS of the stock remained -0.65.Company’s market capitalization is $1.76 billion.
Atlas Resource Partners, L.P. (NYSE:ARP) announced that it has priced an underwritten public offering of 5,500,000 common units representing limited partner interests at an offering price of $21.18. Wells Fargo Securities, Citigroup, Deutsche Bank Securities, J.P. Morgan, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for this offering. The underwriters have been granted a 30-day option to purchase up to an additional 825,000 common units. The net proceeds of the offering, assuming no exercise of the over-allotment option, after underwriting discounts and estimated expenses, are approximately $112.1 million. Atlas Resource Partners, L.P. (NYSE:ARP) stock opened the session at $21.29, and closed the session at $ -3.30.The 52 week range of the ARP stock remained $18.30-$25.71 and the day range was $21.20-$21.86.